Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922933 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02922933 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT02922933, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is therefore to evaluate the effect of concomitant drugs through an increase of intra-gastric pH levels on the bioavailability of entinostat. The primary objectives of this study are to evaluate the effect of multiple doses of omeprazole, famotidine, and the effect of an acidic beverage in combination with omeprazole on the single-dose PK profile of entinostat. The secondary objectives are to evaluate the safety and tolerability of a single dose of entinostat when administered with multiple doses of omeprazole, famotidine, and when administered with an acidic beverage in combination with omeprazole.
Interventions
- DRUG entinostat
- DIETARY_SUPPLEMENT Omeprazole
- DIETARY_SUPPLEMENT Famotidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2017-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922933
The ClinicalTrials.gov registry entry for NCT02922933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which entinostat is the first listed.
NCT02922933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922933 about?
NCT02922933 is a clinical study titled "A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects". The purpose of this study is therefore to evaluate the effect of concomitant drugs through an increase of intra-gastric pH levels on the bioavailability of entinostat. The primary objectives of this study are to evaluate the effect of multiple doses of omeprazole, famotidine, and the effect of an a...
What is the current status of trial NCT02922933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2016-10-25. Estimated completion is 2017-05-08.
What interventions are being tested in trial NCT02922933?
The interventions under investigation include: entinostat (DRUG), Omeprazole (DIETARY_SUPPLEMENT), Famotidine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02922933?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.